Regentis Biomaterials Ltd. Ordinary Shares (RGNT)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable economics, honest accounting, and a margin of safety. Regentis fails most of those tests on the supplied numbers. It is a regenerative medicine company built around Gelrin and GelrinC, with GelrinC still in Phase II for knee cartilage injuries. That is a promising scientific story, but a Phase II product is not a commercial franchise and I see no durable moat in the data. Financially, the picture is weak. At the 2026-10-13 close of $1.63, the market capitalization is only $15.4 million. The P/E is negative at -0.66, so there are no earnings to value. ROCE is -113.59%, and the Piotroski F-Score is 3/9, while the Altman Z-Score is -6.29, which points to distress. The one clear positive is D/E of 0.00, meaning no debt is reported. P/B is 1.49, so the shares are not obviously cheap against accounting book value; with negative returns, book value may not be the right anchor. The 52-week range of $1.23 to $15.50 shows how violently the market has repriced the story, and the current price sits near the low end. Growth is impossible to assess: revenue growth, profit growth, and ROE are listed as N/A, and the Lynch category is none because there are only 0 years of filed results. FairStock Score is 40/100. This is a speculative clinical-stage equity, not a Graham-style bargain. I would need proof of commercial traction, improving cash generation, and trial success before calling it a business rather than an option.

In plain English: Regentis Biomaterials is a small healthcare company working on tissue repair products, including a gel for knee cartilage injuries that is still in mid-stage testing. The business looks weak today because it does not make a profit and has very little financial track record. At $1.63 per share, the price is not clearly cheap or expensive; it mostly reflects hope that the science will work.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer